Novo Nordisk's Balancing Act: Buybacks and Brazil Price Cuts Meet a Cardiology Setback

Novo Nordisk's buybacks signal confidence, but Ziltivekimab setbacks and rising competition cloud the outlook ahead of its capital markets day.

The arithmetic at Novo Nordisk is getting harder to ignore. The Danish pharmaceutical group has been buying back its own shares with conspicuous determination — between 31 August and 4 September alone it acquired 1,055,000 B-shares under a 12-month programme worth 15 billion Danish kroner. Since the buyback began on 4 February, the company has repurchased 32,034,179 shares at an average price of 281.63 kroner, for a total outlay of 9.02 billion kroner. Its treasury now holds 46,074,876 of its own shares, equivalent to one percent of share capital.

Management signalling of that sort usually carries a simple message: the stock is cheap. At 38.54 euros, the shares sit roughly 30 percent below their 52-week high of 54.86 euros, reached in January. Yet buybacks alone rarely resolve structural questions, and Novo Nordisk currently faces several of them at once.

A Pipeline Question That Won't Wait

The most pressing issue is the pipeline setback that emerged in recent weeks. An independent data monitoring committee halted two late-stage Ziltivekimab studies in heart failure, citing a "low probability" of achieving a divergent result. That follows disappointing cardiovascular outcomes for the drug in July. What remains is a single ongoing trial in post-heart-attack patients, with results not expected until the first half of 2027.

Ziltivekimab was meant to be a growth driver beyond the GLP-1 franchise. Its near-collapse within months leaves a hole that management must now address at its capital markets day on 21 September. Investors will be listening for how the company intends to fill that gap — and whether the broader pipeline can carry the weight.

There are counterweights. A study of Semaglutide in children aged 6 to under 12 showed that 40.4 percent of treated children were no longer classified as obese after 68 weeks, with no new safety concerns emerging. That potentially opens an entirely new patient population and reinforces the durability of the GLP-1 platform. Meanwhile, the oral Wegovy tablet launched in Germany last Friday — the first EU market for the formulation — with further countries expected to follow during the year. Since that launch, the stock has slipped 3.7 percent.

Citi, for its part, pointed on 2 September to slowing new-prescription trends for Novo's key obesity GLP-1 products, based on a weekly IQVIA tracker. The exception, notably, is the oral Wegovy variant. The bank maintains a sell rating with a price target of 265 Danish kroner.

Brazil Shows the Price of Patent Expiry

While the next product generation is being contested in the US and Europe, Brazil is already demonstrating what happens to the company's most profitable core business when patent protection lapses. After the Semaglutide patent expired at the end of March, Brazilian health regulator Anvisa has approved nine domestic Semaglutide preparations, priced up to 35 percent below the original. Generic maker Hypera brought its product Semavy to market in September with discounts of up to 67 percent.

Even Novo Nordisk's own distribution partner in the country, Eurofarma, is now offering discounts of up to 39 percent on the biologic Semaglutide products Poviztra and Extensior. The pattern offers a preview of what awaits in other markets as patents fall and generic competition accelerates.

The underlying market opportunity remains substantial: the global GLP-1 market is projected to grow from roughly 12.19 billion US dollars in 2025 to 42 billion US dollars by 2035, a compound annual growth rate of 13.17 percent. Novo Nordisk, alongside Eli Lilly and Sanofi, is a central player in that expansion. But growth does not automatically protect market share when generics and new oral competitors press in simultaneously.

Competition Heats Up in Oral Obesity

The competitive landscape for oral obesity therapies is sharpening in particular. Structure Therapeutics reported weight loss of up to 16.2 percent in a clinical study of its slimming tablet — a result analysts have interpreted as a clear intensification of competition in oral obesity treatment. Phase 3 studies are being prepared. Novo Nordisk is concurrently advancing its own Phase 3 study of oral Semaglutide at a lower dose, fully blinded against placebo and currently in the recruitment phase. The race to deliver the most convenient and effective administration form is far from decided, and that uncertainty is keeping markets on edge.

Personnel Movement Adds to the Picture

There has been board-level movement too. Ulla Grove Krogsgaard Thomsen, who spent 29 years at the company and most recently headed Novo Nordisk Pharmatech, has voluntarily stepped down to position herself outside the organisation — in her words, because "now is the time" to leave her mark elsewhere. The company said it was surprised by the departure. Such exits are not existential, but they fit the profile of a group in the midst of reorganisation.

The Verdict Investors Face

The bull case rests on the paediatric Semaglutide data, the European rollout of the oral tablet, and the possibility that the capital markets day offers concrete progress on these programmes. The bear case is that the Ziltivekimab failure is not an isolated event but a pattern — a central pipeline candidate effectively eliminated within months, while prescription trends for established products show signs of cooling.

For now, the buybacks provide short-term support and signal management's confidence. But the path back to previous highs runs through tangible clinical successes, not balance-sheet cosmetics. The next concrete test arrives on 21 September, when management must answer the pipeline question directly. Until then, the stock remains one for investors prepared to watch that answer closely.